Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Moleculin Biotech (MBRX – Research Report) today and set a price target of $18.00. The company’s shares closed last Tuesday at $3.52, close to its 52-week low of $3.12.
According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 40.8% and a 46.6% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Sensei Biotherapeutics, and Cellectar Biosciences.
Currently, the analyst consensus on Moleculin Biotech is a Moderate Buy with an average price target of $16.00.
Based on Moleculin Biotech’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.45 million. In comparison, last year the company had a GAAP net loss of $1.21 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company’s preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.